We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


T Cells in COVID-19 – Translating Research Findings Into Clinical Options

T Cells in COVID-19 – Translating Research Findings Into Clinical Options content piece image

Analysis of SARS-CoV-2-specific T cells is important in understanding their role during acute disease and in long-term protection after infection or vaccination. Though studying these rare cells comes with challenges, the insights gained offer great opportunities in fighting COVID-19. This webinar will cover both sides.

There is also growing evidence that SARS-CoV-2-specific T cells play an important role in recovery from COVID-19. Researchers have reported the presence of a SARS-CoV-2-specific memory T-cell population in the blood of convalescent donors. These cells could be used to treat COVID-19 patients in certain cases.

At Miltenyi Biotec, we offer a complete workflow for the study of virus-specific T cells. Several preparation methods for clinical-grade cell products have been described that utilize our CliniMACS® Technology.1-3

Attend this webinar to: 

  • Get to know the tools used for SARS-CoV-2-specific T-cell research
  • Learn how to overcome key challenges, such as high sample numbers, low cell frequencies, inefficient stimulation and operator safety
  • Get an overview of published preclinical and clinical data on cell therapy for COVID-19
Dr. Lorenz Fülle
Dr. Lorenz Fülle
Global Product Manager for Antigen- and Virus-Specific T Cells, Miltenyi Biotec
Kirsten Langeveld
Kirsten Langeveld
Global Product Manager, Miltenyi Biotec